본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology v.25 no.4, 2007년, pp.193 - 200  
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

식도암에서 MDM2, p53, pRb 발현과 동시적 항암화학방사선요법의 결과
MDM2, p53 and pRb Expression Prior to Definitive Chemoradiotherapy in Esophageal Carcinoma

윤미선   (전남대학교 의과대학 방사선종양학교실UU0001112  ); 이재혁   (전남대학교 의과대학 병리학교실UU0001112  ); 조상희   (전남대학교 의과대학 혈액종양학교실UU0001112  ); 송주영   (전남대학교 의과대학 방사선종양학교실UU0001112  ); 안성자   (전남대학교 의과대학 방사선종양학교실UU0001112  ); 정익주   (전남대학교 의과대학 혈액종양학교실UU0001112  ); 정웅기   (전남대학교 의과대학 방사선종양학교실UU0001112  ); 나병식   (전남대학교 의과대학 방사선종양학교실UU0001112  ); 남택근   (전남대학교 의과대학 방사선종양학교실UU0001112  );
  • 초록

    목적: 식도암에서 동시적 항암화학방사선치료 전 MDM2, p53, pRb 발현양상이 치료반응 및 생존율 등 치료결과와 연관성이 있는지 알아보고자 하였다. 대상 및 방법: AJCC 병기 $I{\sim}IVa$ 로 근치적 목적의 동시적 항암화학방사선요법을 받은 51명의 환자를 대상으로 하였다. 방사선치료는 일일 $1.8{\sim}2.0$ Gy씩 원발병소에 중앙값 54 Gy를 시행하였고 항암화학요법은 CDDP/5-FU를 4주 간격으로 4회 시행하고 첫 2회는 방사선치료와 동시에 시행하였다. MDM2, p53, pRb 발현의 검출은 치료 전 내시경하 조직생검을 이용하여 면역조직화학 염색방법을 이용하였다. 단백발현 양성종양세포가 50%이상인 경우를 고발현군으로 정의하였다. 전체 환자의 중앙 추적관찰기간은 26개월이었다. MDM2, p53, pRb 고발현군은 각각 19.6%, 27.5%, 66.7% 이었다. 그러나 이들의 발현 정도와 치료반응, 종양특이 생존율, 전체 생존율 등 모두 유의한 연관성은 없었다. 연령(65세 이하 vs. 초과), 종양의 위치(상부, 중앙부, 하부),종양의 길이(5 cm이하 vs. 초과). 병기( $I{\sim}II$ vs. $III{\sim}IVa$ ), MDM2 (저발현 vs. 고발현), p53 (저발현 vs. 고발현), pRb (저발현 vs. 고발현), 병리학적 완전관해여부, 임상적 완전관해여부 등 9개 요인들을 대상으로 종양특성 생존율에 대한 다변량 분석에서 병리학적 완전관해여부(RR 12.100, p


    Purpose: This study evaluated the pretreatment expression patterns of MDM2, p53, and pRb proteins to determine if the expression patterns could predict the outcome of concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma and aid in the decisions for the selection of treatment modalities. Materials and Methods: Fifty-one patients that were treated with definitive chemoradiotherapy for stage $I{\sim}IVa$ esophageal squamous cell carcinoma were selected for this study. Radiotherapy was administered with daily $1.8{\sim}2\;Gy$ fractions up to a median dose of 54 Gy for primary tumors, and with four cycles of cisplatin/5-fluorouracil chemotherapy that was administered every 4 weeks, the first two cycles of which were administered concurrently with radiotherapy. Expression of MDM2, p53, and pRb was investigated by immunohistochemical analysis using pretreatment biopsy specimens. Results: MDM2, p53, and pRb were detected with high immunoreactivity in 19.6%, 27.5%, and 66.7% of the patients, respectively. However, there was no significant correlation between expression of these factors and clinical outcome. By the use of multivariate analysis with nine covariates-age, tumor location, tumor length, stage, pathological response, clinical response, MDM2 expression, p53 expression, and pRb expression, only pathological response and stage were significant factors for cause-specific survival. Conclusion: Expression of MDM2, p53, and pRb was not found to be clinically significant for predicting outcomes after CCRT in this study. Further studies with a larger patient population and longer follow-up periods are needed to re-evaluate the expression pattern and to identify new predictors for CCRT response.


  • 주제어

    식도암 .   항암화학방사선요법 .   면역조직화학염색.  

  • 참고문헌 (35)

    1. Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977;39(2 Suppl):882-890 
    2. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-284 
    3. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245 
    4. Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998;89:221- 227 
    5. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993; 53:846-850 
    6. American Joint Committee on Cancer. Manual for staging of cancer. 6th ed. Philadelphia, PA: Lippincott Co. 2002: 57-61 
    7. Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;57:1328-1335 
    8. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-586 
    9. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958- 9961 
    10. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330 
    11. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86 discussion 86-87 
    12. Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 2002;25:454-459 
    13. Landers JE, Haines DS, Strauss JF 3rd, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-2750 
    14. Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys 2001;49:657-664 
    15. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-698 
    16. Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J. Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol Clin Biol 1995;19:465-474 
    17. Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997;226:162-168 
    18. Puglisi F, Di Loreto C, Panizzo R, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996;49:456-459 
    19. Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-5769 
    20. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-6468 
    21. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000;2:569-573 
    22. Ito T, Kaneko K, Makino R, et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001;36:303-311 
    23. Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined- modality approach. Cancer 2004;100:1859-1867 
    24. Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258-2261 
    25. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83:7-18 
    26. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 
    27. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-2234 
    28. Shimoji H, Miyazato H, Nakachi A, et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000;13:185-190 
    29. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163 
    30. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-2317 
    31. Hur HK, Rha SH, Hong SH. Expression pattern of the Rb protein and its correlation with prognosis in primary lung cancer. Korean J Pathol 1997;31:152-161 
    32. Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 1998;4:251-259 
    33. Kim JH, Choi EK, Kim SB, et al. Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2001; 50:1-12 
    34. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468 
    35. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357- 365 

 저자의 다른 논문

  • 윤미선 (17)

    1. 2005 "방사선치료계획장치로 설계된 Cerrobend 선량보상체와 전자 선량보상체의 제작 및 특성 분석" 의학물리 = Korean journal of medical physics 16 (2): 82~88    
    2. 2006 "위상기반 호흡연동 방사선치료 시 오차 분석 프로그램 개발" 의학물리 = Korean journal of medical physics 17 (3): 136~143    
    3. 2007 "국소 진행된 하인두암의 치료 결과와 예후 인자 분석" 대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology 25 (3): 151~159    
    4. 2007 "Cone-beam CT 영상 획득 시 호흡에 의한 영향 분석" 의학물리 = Korean journal of medical physics 18 (2): 81~86    
    5. 2008 "직장암의 수술 전 동시적 항암화학방사선치료 결과" 대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology 26 (4): 247~256    
    6. 2008 "폐암 환자의 방사선수술 시 호흡연동 방사선치료 방법의 적용을 통한 계획용표적체적 감소 효과 분석" 의학물리 = Korean journal of medical physics 19 (4): 263~268    
    7. 2010 "항문암 환자에서 근치적 목적의 동시 항암화학 방사선치료의 결과" 대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology 28 (4): 205~210    
    8. 2010 "토모테라피에서 계획용표적체적 설정 시 필드 폭 영향 분석" 의학물리 = Korean journal of medical physics 21 (4): 323~331    
    9. 2011 "토모테라피를 이용한 폐종양 방사선수술 계획 시 선량 분석" 의학물리 = Korean journal of medical physics 22 (4): 178~183    
    10. 2012 "유방암의 접선 세기조절 방사선치료 선량 특성 분석" Progress in Medical Physics = 의학물리 23 (4): 219~228    
  • 이재혁 (3)

  • Cho, Sang-Hee (6)

  • 송주영 (24)

  • Ahn, Sung-Ja (50)

  • Chung, Ik-Joo (10)

  • Chung, Woong-Ki (48)

  • 나병식 (36)

  • 남택근 (41)

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • NDSL :
  • 대한방사선종양학회 : 저널
유료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 이용한 콘텐츠
이 논문과 함께 출판된 논문 + 더보기